Lecture Notes: Discussion with Dr. William Mackus on Cancer and Repurposed Drugs

Introduction

• Presenter: Dr. William Mackus
• Background: Born in Czechoslovakia, fled communism, settled in Canada.
• Education: University of Toronto (Immunology), McGill University (Medical Degree), specialization in Nuclear Medicine, Radiology, Oncology.
• Professional Experience: Oncology clinics, over 100 peer-reviewed publications.

Targeted Radionuclide Therapy

• Concept: Advanced technology over external beam radiation.
• Method: Injected radioactive molecules target cancer cells with minimal impact on healthy tissues.
• Challenges: Program was sabotaged and copied by Canadian government.

Rise of Aggressive Cancers

• Observation: Increase in aggressive cancers since 2022, termed as "turbo cancer."
• Characteristics:
  • Young individuals presenting with stage 4 cancers.
  • Resistance to conventional treatments (chemotherapy, radiotherapy, immunotherapy).
  • Oncologists’ prognosis off by a factor of 10.
• Possible Causes: Suggestion of new pathophysiology.

Turbo Cancers

• Definition: Not a professional term but describes aggressive, fast-progressing cancers.
• Common Types: Lymphomas, brain cancers, breast and colon cancers.
• Impact: Affecting younger populations, alarming oncologists and pathologists.
• Current Reaction: Mainstream oncology lowering screening age but not researching underlying causes.

Environmental Factors and COVID-19

• Temporal Correlation: Rise in cancers post-COVID pandemic and vaccine rollout.
• Possible Contributors: COVID-19 virus waves, mRNA vaccines.
• Censorship and Advocacy: Dr. Mackus faced censorship, used social media to raise awareness.

Repurposed Drugs in Cancer Treatment

• Interest: Dr. Mackus explored early treatments for COVID-19 and discovered preclinical research on drugs like ivermectin in cancer.
• Notable Drugs:
  • Ivermectin: Shows promise in targeting cancer stem cells, reversing drug resistance, and acting as a radiosensitizer.
  • Fenbendazole/Mebendazole: Anti-parasitics with potential cancer treatment properties.
• Challenges: Lack of human trials due to no financial incentive.

Treatment Protocols with Repurposed Drugs

• Approach: Combine repurposed drugs with conventional treatments for synergy.
• Dosing:
  • Ivermectin: 1 mg/kg/day, monitored over three months.
  • Fenbendazole/Mebendazole: 1000 mg/day, six days on, one day off.
• Results: Anecdotal reports of tumor shrinkage and improved patient outcomes.

Future of Medicine

• Repurposed Drugs: Potential to become mainstream with further research and trials.
• Barriers: Current medical guidelines restrict off-label use, leading to ethical dilemmas.
• Hope for Change: Calls for transparency and broader acceptance of treatment options based on patient benefit.

Miscellaneous

• Impact of Vitamin D: Important for immune system support, often overlooked in cancer patients.
• Medicinal Mushrooms: Turkey tail and others show promise in cancer treatment due to immunomodulatory effects.

Conclusion

• Vision: Dr. Mackus advocates for a shift in medicine towards embracing repurposed drugs to provide patients with more options and hope.
• Call to Action: Encourages openness to new approaches and increased research on unconventional cancer treatments.